Nivolumab (Nivo) + ipilimumab (Ipi) vs platinum-doublet chemotherapy (Chemo) as first-line (1L) treatment (Tx) for advanced non-small cell lung cancer (NSCLC): Safety analysis and patient-reported outcomes (PROs) from CheckMate 227 Meeting Abstract
| Authors: | Reck, M.; Hellmann, M. D.; Paz-Ares, L. G.; Ramalingam, S. S.; Brahmer, J. R.; O'Byrne, K. J.; Bhagavatheeswaran, P.; Nathan, F. E.; Borghaei, H. |
| Abstract Title: | Nivolumab (Nivo) + ipilimumab (Ipi) vs platinum-doublet chemotherapy (Chemo) as first-line (1L) treatment (Tx) for advanced non-small cell lung cancer (NSCLC): Safety analysis and patient-reported outcomes (PROs) from CheckMate 227 |
| Meeting Title: | 54th Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 36 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2018 Jun 1-5 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2018-05-20 |
| Start Page: | 465s |
| Language: | English |
| ACCESSION: | WOS:000442916003194 |
| DOI: | 10.1200/JCO.2018.36.15_suppl.9020 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 9020 -- Source: Wos |
